SafeHeal is a medical technology company focused on developing innovative devices to enhance postoperative care for patients undergoing treatment for colorectal cancer. The company has created a flexible bypass sheath that employs a vacuum-based mechanism, which remains in place until the body's natural healing processes are complete. This device is specifically designed to protect gastrointestinal anastomosis, thereby improving the quality of life for patients during recovery. SafeHeal was established by MD Start, a medtech accelerator, and is backed by funding from MD Start and Sofinnova Partners. The company has received several accolades for its innovation, including recognition in the Worldwide Innovation Challenge and the iLab grant program, as well as being named the most promising MedTech startup at Biovision 2016 and a finalist in the global Medtech Innovator competition. Additionally, SafeHeal was awarded the Charles Foix grant for its contributions to enhancing the quality of life for elderly individuals.
Forth Therapeutics is a pioneering precision therapeutics that target the underlying mechanisms driving fibrosis.
Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.
Latent Labs is making biology programmable to transform health and sustainability for the benefit of all. We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizing existing enzymes, and advancing genetic engineering. Contact us to work with us today.
Berry Street operates an online telehealth platform that specializes in nutrition therapy for various health conditions, including disordered eating, heart health, PCOD, liver disease, women's health, sports nutrition, and diabetes. The platform connects patients with board-certified dietitians, facilitating care through video and chat services. By partnering with numerous insurance plans, Berry Street ensures that patients can access these essential services without incurring out-of-pocket expenses, ultimately helping them achieve their health goals and enhance their quality of life.
Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.
Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.
Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals with degenerative ocular diseases. The company's innovative platform focuses on creating treatments that can be delivered directly to the eye, eliminating the need for systemic administration. This targeted approach enhances the potential for effective intervention, allowing healthcare providers to significantly improve the quality of life for patients suffering from various eye conditions. Through its commitment to advancing vision-restoring technologies, Tenpoint Therapeutics is positioned to make a meaningful impact in the field of ocular health.
Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.
Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.
Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.
Purespring Therapeutics is an innovative company dedicated to developing gene therapies for kidney diseases, with a strong emphasis on podocytes, the specialized cells in the kidneys. As one of the pioneers in utilizing AAV gene therapy for renal conditions, Purespring aims to address significant unmet medical needs in this challenging area of healthcare. The company has established an in-vivo functional screening platform designed to identify protective factors that could be beneficial across a range of kidney diseases, while also exploring applications for gene therapy in cardiovascular disorders. Through its focused approach, Purespring is positioned to make a meaningful impact in the treatment of renal conditions.
Genespire is a biotechnology company dedicated to advancing gene therapies for individuals suffering from genetic disorders, with a specific emphasis on primary immunodeficiencies and inherited metabolic diseases. The company specializes in developing innovative therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for the precise and effective insertion of therapeutic genes into blood cells, providing patients with a range of tailored treatment options suitable for their unique conditions. Genespire's mission is to transform the lives of patients affected by severe genetic diseases through cutting-edge therapeutic solutions.
Novameat is a company focused on developing innovative technological solutions for producing plant-based foods to address the challenges posed by conventional animal agriculture. Through its proprietary micro-extrusion technology, Novameat creates vegan meat substitutes that closely mimic the texture, appearance, taste, and nutritional properties of various animal meat products, including beef steaks. The company's mission is to support a sustainable and efficient food supply system that meets the needs of the growing global population while promoting health and humane practices. By providing affordable and healthy plant-based meat options, Novameat aims to contribute to a more sustainable future in food production.
deepc GmbH, based in Munich, Germany, specializes in developing AI software for medical imaging, particularly in radiology, to minimize diagnostic errors. The company offers a disease-agnostic AI solution that analyzes medical imaging data in real-time, identifying healthy and non-healthy cases to enhance diagnostic accuracy. Its web-based AI software framework, referred to as the Diagnostics OS, facilitates the integration of various medical diagnostic AI tools into clinical workflows, improving efficiency and cost-effectiveness. By serving as a central hub for artificial intelligence applications in radiology, deepc aims to support healthcare professionals in achieving faster, more accurate diagnoses, ultimately leading to better patient outcomes. The company has received recognition for its innovative contributions, including awards from the Federal Ministry for Economic Affairs and Energy.
Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.
Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.
May Health specializes in developing innovative solutions for infertility related to Polycystic Ovary Syndrome (PCOS). The company offers a minimally invasive procedure aimed at restoring ovulation in women with PCOS, providing a more natural approach to pregnancy. This one-time treatment is performed transvaginally under ultrasound guidance, eliminating the need for general anesthesia. The procedure is designed to assist the body's natural ovulation process and can be conducted in a clinical setting, similar to techniques used by fertility specialists in in vitro fertilization (IVF). May Health's focus is on delivering effective, durable solutions for patients seeking to conceive while minimizing the medicalization of the pregnancy experience.
Cure51 is focused on building a comprehensive database of cancer survivors to harness their unique biological characteristics in the pursuit of new cancer therapies. The company develops a clinical and molecular database aimed at expediting drug discovery by analyzing the biology of long-term cancer survivors. This approach allows researchers to identify potential targets for drug development by decoding genetic information from various sources, including biopsies, blood tests, and imaging. By leveraging insights gained from this data, Cure51 aims to contribute to the formulation of innovative treatments for cancer.
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.
Private Equity Round in 2024
Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.
Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.
Sensorion is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. The company's lead product, SENS-401, is currently in phase II clinical trials aimed at treating sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-111, which is in phase II trials for acute unilateral vestibulopathy, and SENS-300, which is in the pre-clinical stage for addressing inner ear toxicity. The company also collaborates with Cochlear Limited to explore combination therapies for patients with cochlear implants. Founded in 2009, Sensorion is dedicated to conducting research and development to discover drugs that can restore and treat hearing loss, positioning itself as a key player in the field of otology.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.
DISCO Pharmaceuticals is a company focused on advancing cancer treatment through its innovative surfaceome mapping platform. This technology enables the identification of proteins and protein communities on the cancer cell surface at a large scale, providing detailed insights that traditional proteomics and genomic methods cannot offer. By unlocking the surfaceome of cancer cells, DISCO Pharmaceuticals aims to facilitate the development of cancer-selective therapies that enhance treatment efficacy while minimizing side effects for patients. The company's approach holds promise for improving patient care by enabling more targeted and effective therapeutic options in oncology.
Qorium is a biotechnology company focused on producing sustainable, cell-cultured collagen-based leather. By utilizing advanced cell culturing and tissue engineering technologies, Qorium aims to minimize the environmental impact associated with traditional leather manufacturing. The company's innovative approach provides a premium alternative to conventional leather, which is often linked to issues such as deforestation and the meat industry. As a result, Qorium offers a viable option for consumers seeking animal-free leather products while promoting sustainability in the fashion and materials industries.
GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.
Freya Biosciences is a clinical-stage company focused on women's health, with operations in Copenhagen and Boston. It specializes in developing microbial immunotherapies aimed at addressing significant unmet medical needs across various conditions. The company utilizes a proprietary platform to engineer and manufacture live microbes, ensuring their safety and efficacy for human use. Through this innovative approach, Freya Biosciences seeks to create new treatment options for a range of diseases, striving to make a meaningful impact in the healthcare sector.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.
T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.
Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.
Betteromics is a SaaS platform designed to enhance data analysis in the life sciences industry through advanced AI and computational techniques. The platform operates as a Private SaaS within a Virtual Private Cloud (VPC), facilitating seamless connections across diverse data sources. It offers a centralized and objective source of truth, enabling team members to access reliable information and create accurate descriptions. Founded by seasoned professionals with backgrounds in Google and GRAIL, Betteromics combines expertise from academia, science, and technology to empower users to efficiently collect, process, and analyze complex multi-modal molecular datasets. This capability allows users to make informed decisions more swiftly, ultimately advancing their research and operational goals.
l'école AI is a computer vision-focused development platform. Its objective is to enable humans to use AI with purpose to change the future, beginning with a focus on speeding advances in life sciences using computer vision.
Bon Vivant is a French biotechnology startup founded by Hélène Briand and Stéphane Mac Millan, specializing in the development of plant-based milk alternatives. The company utilizes precision fermentation technology to create non-dairy products that closely mimic the texture and taste of traditional dairy. By cultivating milk proteins in a vegetable culture medium, Bon Vivant aims to provide accessible and pure alternatives to cheese and other dairy items, catering to consumers seeking dairy-free options without compromising on quality.
Sitryx Therapeutics is a biopharmaceutical company founded in 2018 and headquartered in Oxford, United Kingdom. The company focuses on developing innovative disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. Sitryx aims to enhance immune cell functions to inhibit tumor growth and improve immune responses. Co-founded by leading scientists from the United States and Europe, the company has attracted significant investment, including $30 million in Series A funding from a consortium of specialist investors. Sitryx has established a diverse pipeline of projects at various stages of drug discovery, positioning itself at the forefront of immunometabolism research.
Gradient Denervation Technologies is a Paris-based company founded in 2019 that focuses on the development of an endovascular catheter-based medical device designed to treat pulmonary hypertension. This innovative technology aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics through a minimally invasive procedure. The device is built on prior research and intellectual property developed at Stanford University and offers a novel approach to pulmonary artery denervation, addressing heart failure and associated pulmonary hypertension. By providing a reliable and effective treatment option, the company seeks to improve patient outcomes in the healthcare industry.
Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.
Sensorion is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. The company's lead product, SENS-401, is currently in phase II clinical trials aimed at treating sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-111, which is in phase II trials for acute unilateral vestibulopathy, and SENS-300, which is in the pre-clinical stage for addressing inner ear toxicity. The company also collaborates with Cochlear Limited to explore combination therapies for patients with cochlear implants. Founded in 2009, Sensorion is dedicated to conducting research and development to discover drugs that can restore and treat hearing loss, positioning itself as a key player in the field of otology.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals with degenerative ocular diseases. The company's innovative platform focuses on creating treatments that can be delivered directly to the eye, eliminating the need for systemic administration. This targeted approach enhances the potential for effective intervention, allowing healthcare providers to significantly improve the quality of life for patients suffering from various eye conditions. Through its commitment to advancing vision-restoring technologies, Tenpoint Therapeutics is positioned to make a meaningful impact in the field of ocular health.
AAVantgarde Bio is a biotechnology company focused on developing gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This innovative approach allows for the delivery of large genes to both ocular and non-ocular tissues, enhancing the potential for effective gene therapy solutions. By addressing these challenges, AAVantgarde Bio aims to improve treatment outcomes for patients suffering from these genetic conditions.
BrightHeart is a medical technology startup that is developing artificial intelligence software to help diagnose congenital heart abnormalities in foetuses.
TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.
Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.
Werewool is engaged in the development of a biomaterials platform focused on creating biodegradable fibers for sustainable textiles. The company's innovative approach involves designing fibers at the DNA level, allowing for tailored aesthetic and performance properties, such as color, moisture management, and stretch. This technology aims to support the fashion industry in producing apparel that minimizes environmental impact, promoting a more sustainable approach to textile production.
Alia Therapeutics focuses on developing advanced gene-editing medicines aimed at curing rare genetic diseases. The company employs innovative CRISPR-based genome editing tools to target and correct inborn genetic errors directly within patients' cells. By utilizing these unique therapeutic approaches, Alia Therapeutics seeks to address genetic disorders at their source, providing healthcare professionals with the means to modify genomes effectively. Additionally, the company emphasizes safe and efficient delivery mechanisms to ensure the targeted treatment of affected cells.
deepc GmbH, based in Munich, Germany, specializes in developing AI software for medical imaging, particularly in radiology, to minimize diagnostic errors. The company offers a disease-agnostic AI solution that analyzes medical imaging data in real-time, identifying healthy and non-healthy cases to enhance diagnostic accuracy. Its web-based AI software framework, referred to as the Diagnostics OS, facilitates the integration of various medical diagnostic AI tools into clinical workflows, improving efficiency and cost-effectiveness. By serving as a central hub for artificial intelligence applications in radiology, deepc aims to support healthcare professionals in achieving faster, more accurate diagnoses, ultimately leading to better patient outcomes. The company has received recognition for its innovative contributions, including awards from the Federal Ministry for Economic Affairs and Energy.
Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
Mediar Therapeutics is a pre-clinical stage biotechnology company based in Cambridge, Massachusetts, focused on developing antibody-based therapeutics for the treatment of fibrosis. Founded in 2019, the company aims to provide innovative solutions by targeting key fibrotic mediator proteins that contribute to the development of fibrosis in chronically damaged organs. Through its research and development efforts, Mediar seeks to enable medical practitioners to halt and potentially reverse critical fibrosis and related conditions, addressing a significant unmet need in the field of fibrotic diseases.
Nuage Therapeutics is a pharmaceutical company which utilizes chemical biology and biomolecular condensation to develop selective drugs that target proteins with disordered regions for challenging indications to improve patient’s life. The focus of the medication is to enhance selective inhibitors of intrinsically disordered proteins involved in challenging indications in order to meet unmet medical needs.
Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.
Chroma Medicine is a genomic medicine company based in Cambridge, Massachusetts, founded in 2021. The company focuses on epigenetic editing, aiming to revolutionize the treatment of genetically driven diseases. By utilizing epigenetics, which is nature's inherent mechanism for regulating genes, Chroma Medicine develops programmable epigenetic editors that target specific genes and control chromatin conformation. This innovative approach combines a DNA binding domain with epigenetic effector domains, providing medical practitioners with a new class of therapeutics that offers enhanced control over gene expression.
Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.
EnginZyme AB is a biotechnology company based in Stockholm, Sweden, founded in 2014. The company specializes in biocatalysis and a cell-free synthetic biology platform to create sustainable alternatives to conventional materials such as plastics, nylons, and rubbers. EnginZyme's innovative approach focuses on biomanufacturing techniques that promote green chemistry across various industries, including pharmaceuticals, food, chemicals, flavors, and fragrances. By utilizing patented cell-free technology, EnginZyme aims to replace traditional fossil-based manufacturing, thus facilitating the shift toward environmentally friendly production methods. The company has gained recognition for its contributions to sustainability, being named a Global Cleantech 100 company and recognized as a Technology Pioneer by the World Economic Forum. EnginZyme is supported by a diverse group of investors, reflecting its potential impact on addressing climate change and promoting sustainable practices in manufacturing.
Microphyt specializes in the research, development, production, and marketing of natural algae-based products aimed at enhancing health and wellness. The company focuses on creating bioactive dietary supplements that support weight loss and brain health. Utilizing an industrial-scale supply of microalgae biomass and extracts, Microphyt ensures the preservation of cell integrity while producing commercial quantities of slow-growing or biofilm-forming species. This approach enables the healthcare industry to effectively meet the demands of personal care and food products, positioning Microphyt as a key player in the market for natural health solutions.
Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC).
Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.
Private Equity Round in 2022
F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.
Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, specializing in the development of biocatalysts for the fermentation of fine chemicals. Established in 2012, the company leverages innovative high-throughput screening technology to create tailored processes that facilitate the efficient production of complex chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives. By utilizing biocatalysis, Biosyntia aims to significantly reduce production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers to promote sustainable manufacturing processes, contributing to a greener future in the chemical industry.
Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.
Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.
Prometheus Materials focuses on the development of bio-cement designed to achieve zero carbon emissions, contributing to global sustainability efforts. The company specializes in creating innovative construction materials that utilize algae, water, ambient carbon dioxide, sunlight, and sand. By producing bio-cement and bio-concrete that are carbon negative, Prometheus Materials enables clients to adopt more sustainable practices in construction, thereby helping to reduce overall carbon dioxide emissions associated with traditional concrete production.
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.
Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.
SafeHeal is a medical technology company focused on developing innovative devices to enhance postoperative care for patients undergoing treatment for colorectal cancer. The company has created a flexible bypass sheath that employs a vacuum-based mechanism, which remains in place until the body's natural healing processes are complete. This device is specifically designed to protect gastrointestinal anastomosis, thereby improving the quality of life for patients during recovery. SafeHeal was established by MD Start, a medtech accelerator, and is backed by funding from MD Start and Sofinnova Partners. The company has received several accolades for its innovation, including recognition in the Worldwide Innovation Challenge and the iLab grant program, as well as being named the most promising MedTech startup at Biovision 2016 and a finalist in the global Medtech Innovator competition. Additionally, SafeHeal was awarded the Charles Foix grant for its contributions to enhancing the quality of life for elderly individuals.
Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.
Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.
DMC Biotechnologies, Inc. is a biotechnology company based in Boulder, Colorado, that specializes in developing bio-based products through microbial fermentation technology. Founded in 2014, the company focuses on producing specialty chemicals, flavors, fragrances, nutraceuticals, natural products, and pharmaceuticals. Utilizing its Dynamic Metabolic Control technology, DMC Biotechnologies aims to enhance the efficiency and sustainability of production processes, reducing both energy consumption and resource use. This innovative approach allows for quicker development timelines and lower costs, supporting a transition towards a more sustainable economy.
HotSpot Therapeutics is a biotech startup established in 2017 and based in Boston, Massachusetts. The company specializes in developing allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for a range of conditions, including cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and employing data science, HotSpot Therapeutics aims to enhance drug discovery and provide effective treatment options for patients with various health issues.
Synthace Limited is a company focused on transforming the way biological experimentation is conducted across various sectors, including health, pharmaceuticals, food, energy, agri-science, and industrial biotechnology. Established in 2011 and headquartered in London, with an additional office in Cambridge, Massachusetts, Synthace offers a cloud-based platform called Antha. This platform enables life science research and development teams to streamline their experimental processes by allowing scientists to design, plan, and execute reproducible experiments without requiring coding skills. Antha facilitates the automation of laboratory experiments and the organization of experimental data, making it easier for researchers to run complex experiments that might have been previously deemed impractical. The company has also formed a strategic partnership with Microsoft to enhance its offerings.
Home Biosciences is a European venture builder dedicated to biotech.
GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.
Nitrase Therapeutics is a biopharmaceutical platform company focused on developing therapies targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, the company aims to create drugs that may slow or halt the progression of this and other related neurodegenerative conditions. By leveraging its expertise in nitration, Nitrase Therapeutics seeks to explore the therapeutic potential of biochemical modifications of proteins, particularly through the identification of nitro-substrates and their involvement in various diseases. This approach positions the company to potentially expand its platform to address a broader range of medical conditions in the future.
Sphere Fluidics Limited is a new Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.
Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.
Leucid Bio is a biotechnology company focused on developing innovative cell therapies for patients with refractory cancers, particularly solid tumors. Founded to leverage two decades of research from King's College London in the CAR-T field, Leucid Bio is guided by a seasoned management team possessing both scientific and commercial expertise. The company has a strong partnership with King's College, granting it exclusive access to a wealth of scientific, clinical, and manufacturing resources, particularly from Dr. Maher and his team of immuno-oncology specialists. By specializing in advanced CAR T-cell therapies, Leucid Bio aims to enhance treatment outcomes and provide durable responses for patients who have limited or no treatment options available.
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, established in 2018. The company is dedicated to developing clinical candidates targeting cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at treating resistant hypertension and primary aldosteronism. CinCor Pharma's mission is to advance its promising clinical candidates toward marketing approval, emphasizing the development of innovative therapies for patients suffering from cardio-renal conditions.
iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The firm focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx Therapeutics has identified several new targets and examined their mechanisms of action. The company's foundation is built upon the principles of cancer immune-checkpoint therapy, which aims to overcome the resistance mechanisms that tumors utilize to evade immune attacks. These resistance mechanisms often involve specific cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.
TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.
Protera specializes in the development of functional ingredients for the food industry through protein engineering and artificial intelligence. The company utilizes a proprietary deep-learning algorithm to enhance the design and development of proteins and enzymes, enabling the rapid prediction of high-value food products. This innovative approach allows Protera to address ethical, environmental, and consumer health challenges while producing ingredients that are both healthy and sustainably sourced. By streamlining the protein design process, Protera supports customers in bringing safe and nutritious foods to market more efficiently and cost-effectively.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.
Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
Muna Therapeutics is a biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases, such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying new medicines that preserve cognitive function and enhance resilience against these debilitating conditions, thereby providing individuals affected by neurodegenerative diseases with access to effective treatment options. Through its innovative approach, Muna Therapeutics strives to improve the quality of life for those suffering from these challenging disorders.
Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.
Alia Therapeutics focuses on developing advanced gene-editing medicines aimed at curing rare genetic diseases. The company employs innovative CRISPR-based genome editing tools to target and correct inborn genetic errors directly within patients' cells. By utilizing these unique therapeutic approaches, Alia Therapeutics seeks to address genetic disorders at their source, providing healthcare professionals with the means to modify genomes effectively. Additionally, the company emphasizes safe and efficient delivery mechanisms to ensure the targeted treatment of affected cells.
AAVantgarde Bio is a biotechnology company focused on developing gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This innovative approach allows for the delivery of large genes to both ocular and non-ocular tissues, enhancing the potential for effective gene therapy solutions. By addressing these challenges, AAVantgarde Bio aims to improve treatment outcomes for patients suffering from these genetic conditions.
Mnemo Therapeutics is a biotechnology firm focused on developing immune-based therapies, particularly cell therapies, aimed at treating solid tumors and blood cancers. The company utilizes its EnfiniT platform, a drug discovery engine that harnesses a unique class of antigens and various technologies to target tumorous epitopes prevalent in multiple cancer types. By leveraging epigenetic variation and CAR-T precision genetic engineering, Mnemo Therapeutics strives to create accessible allogeneic treatments that offer effective solutions for patients facing these challenging diseases.
Private Equity Round in 2021
Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.
CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.
Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.